Clinical Trial Detail

NCT ID NCT03070002
Title Denosumab in Treating Patients With ER and/or PR Positive, HER2 Negative Metastatic Breast Cancer With Bone Metastases and Detectable Circulating Tumor Cells
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Northwestern University
Indications

Her2-receptor negative breast cancer

Therapies

Denosumab

Age Groups: adult senior

Additional content available in CKB BOOST